Last reviewed · How we verify

NCT05791721

Effect of Preemptive Etoricoxib and Dexamethasone on Wound Healing and Clinical Parameters After Third Molar Surgery

Completed Phase 4 Last updated 30 March 2023
What this trial tests

Phase 4 trial testing Etoricoxib 90 Mg Oral Tablet in Surgical Wound in 90 participants. Completed in 26 December 2022.

Timeline
11 October 2021
Primary endpoint
26 December 2022
26 December 2022

Quick facts

Lead sponsorUniversity of Belgrade
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Enrollment90
Start date11 October 2021
Primary completion26 December 2022
Estimated completion26 December 2022
Sites1 location across Serbia

Drugs / interventions tested

Conditions studied

Sponsor

University of Belgrade

Who can join

Adults 18 to 30, any sex, with Surgical Wound or Post Operative Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare preemptive single-dose selective cyclooxygenase 2 (COX-2) inhibitor - etoricoxib and dexamethasone use in systemically healthy patients during the surgical extraction of impacted mandibular third molars. The main questions it aims to answer/evaluate are: * the level of inflammatory and early wound healing mediators in patients' saliva during early postoperative phase * clinical postoperative parameters such as pain, swelling and trismus * patient satisfaction with the treatment * rescue medication consumed during the postoperative period * incidence of adverse events Participants indicated for mandibular third molar surgery will be asked to: * take premedication (etoricoxib or dexamethasone) before surgical extraction * provide saliva samples before and following the surgery at regular check-ups * note the amount of rescue medication taken and pain intensity in different time points * perform clinical measurements of swelling and trismus at regular check-up visits * answer the questions about satisfaction and potential adverse events, if occur Researchers will compare preemptive single-dose etoricoxib, preemptive single-dose dexamethasone, and no premedication in impacted mandibular third molar surgery, to see if there are differences in inflammatory response and early wound healing, as well as in clinical postoperative parameters, patient satisfaction with the treatment and incidence of potential adverse events.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Comparison of preemptive etoricoxib and dexamethasone in third molar surgery - a randomized controlled clinical trial of patient-reported and clinical outcomes.
    Mijailovic I, Janjic B, Milicic B, Todorovic A, et al · · 2023 · cited 1× · PMID 37452140 · DOI 10.1007/s00784-023-05146-4

Verify or expand the search:

Other recruiting trials for Surgical Wound

Currently open trials in the same condition.

Other University of Belgrade trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05791721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing